Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

100.27

-0.40 (-0.40%)

At close: Nov 13, 2026, 4:00 PM EST

99.48

-0.79 (-0.79%)

After-hours: Nov 13, 2026, 7:56 PM EST

Halozyme Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1,030	133.82	115.85	118.37	234.2	118.72
Short-Term Investments	44.4	9	480.22	217.63	128.6	622.2
Cash & Short-Term Investments	1,074	142.82	596.07	336	362.79	740.92
Cash Growth	53.05%	-76.04%	77.40%	-7.38%	-51.03%	101.33%
Accounts Receivable	525.59	439.66	308.46	234.21	231.07	90.98
Other Receivables	-	1.61	-	-	-	-
Receivables	525.59	441.27	308.46	234.21	231.07	90.98
Inventory	132.61	176.48	141.86	127.6	100.12	53.91
Prepaid Expenses	112.24	64.64	38.95	48.61	45.02	40.48
Total Current Assets	1,847	825.21	1,085	746.42	739.01	926.29
Property, Plant & Equipment	82.29	82.14	75.04	74.94	75.57	8.79
Goodwill	581.73	580.36	416.82	416.82	409.05	-
Other Intangible Assets	892.93	981.47	401.83	472.88	546.65	-
Long-Term Deferred Tax Assets	-	-	3.86	4.39	44.43	155.43
Other Long-Term Assets	69.67	56.15	80.6	17.82	26.8	13.91
Total Assets	3,473	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	33.55	20.9	10.25	11.82	17.69	1.54
Accrued Expenses	136.93	144.92	128.85	100.68	97.66	22.17
Current Portion of Long-Term Debt	305.61	-	-	-	13.33	89.42
Current Portion of Leases	-	11.28	-	-	2.1	2.28
Current Unearned Revenue	-	-	-	-	-	1.75
Total Current Liabilities	476.09	177.09	139.1	112.49	130.79	117.15
Long-Term Debt	2,945	2,143	1,506	1,499	1,493	787.26
Long-Term Leases	28.82	23.29	-	32.2	32.69	0.54
Long-Term Unearned Revenue	-	-	-	-	-	2.53
Long-Term Deferred Tax Liabilities	6.34	42.92	-	-	-	-
Other Long-Term Liabilities	72.64	90.57	54.76	5.52	15.47	-
Total Liabilities	3,529	2,477	1,700	1,649	1,672	907.48

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.11	0.12	0.12	0.13	0.14	0.14
Additional Paid-In Capital	-	12	-	2.41	27.37	256.35
Retained Earnings	-58.13	54.79	359.87	90.55	143.22	-58.91
Comprehensive Income & Other	2.78	-18.09	3.83	-9.28	-0.92	-0.62
Shareholders' Equity	-55.24	48.81	363.82	83.81	169.8	196.95
Total Liabilities & Equity	3,473	2,525	2,063	1,733	1,842	1,104

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	3,279	2,177	1,506	1,531	1,541	879.49
Net Cash (Debt)	-2,205	-2,034	-909.72	-1,195	-1,178	-138.57
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-18.02	-16.42	-7.03	-8.91	-8.38	-0.94
Filing Date Shares Outstanding	114.01	118.02	123.15	126.82	135.37	137.7
Total Common Shares Outstanding	113.94	117.78	123.14	126.77	135.15	137.5
Working Capital	1,371	648.12	946.24	633.93	608.22	809.14
Book Value Per Share	-0.48	0.41	2.95	0.66	1.26	1.43
Tangible Book Value	-1,530	-1,513	-454.83	-805.89	-785.9	196.95
Tangible Book Value Per Share	-13.43	-12.85	-3.69	-6.36	-5.81	1.43
Machinery	77.65	68.2	57.53	50.78	43.13	18.26
Leasehold Improvements	7.52	7.52	7.01	6.99	6.73	1.63
Order Backlog	-	289.5	-	-	-	-

SEC Filings: 10-K · 10-Q